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hypotension, or acute renal failure occurred in the trial. TheseAdd-on angiotensin receptor blockade with maximized ACE
results were not attributable to sequence or carryover effects.inhibition.
Conclusions. Add-on losartan therapy did not improve pro-Background. Prolonged angiotensin-converting enzyme
teinuria or ABP over one month of add on therapy. Improve-(ACE) inhibitor therapy leads to angiotensin I (Ang I) accumu-
ment of GFR and fall in plasma renin activity suggest thatlation, which may “escape” ACE inhibition, generate Ang II,
renal hemodynamic and endocrine changes are more sensitivestimulate the Ang II subtype 1 (AT1) receptor, and exert dele-
measures of AT1 receptor blockade. Whether add-on AT1terious renal effects in patients with chronic renal diseases.
receptor blockade causes antiproteinuric effects or long-termWe tested the hypothesis that losartan therapy added to a
background of chronic (.3 months) maximal ACE inhibitor renal protection requires larger and longer prospective, ran-
therapy (lisinopril 40 mg q.d.) will result in additional Ang II domized controlled trials.
antagonism in patients with proteinuric chronic renal failure
with hypertension.
Methods. Sixteen patients with proteinuric moderately ad-
Patients with uncontrolled hypertension and protein-vanced chronic renal failure completed a two-period, crossover,
uria have an accelerated decline in renal function [1, 2].randomized controlled trial. Each period was one month with
a two-week washout between periods. In one period, patients In particular, when proteinuria is uncontrolled with angio-
received lisinopril 40 mg q.d. along with other antihypertensive tensin-converting enzyme (ACE) inhibition, patients have
therapy, and in the other, losartan 50 mg q.d. was added to the
a more rapid decline in glomerular filtration rate (GFR)previously mentioned regimen. Hemodynamic measurements
over the long term [3]. Chronic ACE inhibitor therapyincluded ambulatory blood pressure monitoring (ABP; Space-
labs 90207), glomerular filtration rate (GFR) with iothalamate may lead to accumulation of angiotensin I (Ang I) and
clearances and cardiac outputs by acetylene helium rebreathing stimulation of Ang II subtype 1 (AT1) receptor despite
technique. Supine plasma renin activity and plasma aldosterone ACE inhibition. This accumulation of Ang II by stimulat-and 24-hour urine protein were measured in all patients.
ing the AT1 receptor can cause deleterious effects suchResults. Twelve patients had diabetic nephropathy, and four
as vasoconstriction, salt retention, inflammation, and fi-had chronic glomerulonephritis. The mean age (6 SD) was 53 6
9 years. The body mass index was 38 6 5.7 kg/m2, and all except brosis [4], and enhance the activity of the sympathetic
two patients were males. Seated cuff blood pressure was 156 6 nervous system by direct effects on the central and pe-
18/88 6 12 mm Hg. The pulse rate was 77 6 11 per min, and
ripheral adrenergic transmission [5]. Half of the variancethe cardiac index was 2.9 6 0.5 L/min/m2. Mean log 24-hour
in ACE activity is dictated by ACE insertion-deletionprotein excretion/g creatinine or overall ABPs did not change.
Mean placebo subtracted, losartan-attributable change in protein polymorphism [6], such that it dictates the conversion
excretion was 11% (95% CI, –20% to 28%, P 5 0.89). Simi- of infused Ang I to Ang II [7], the systemic [8] and renal
larly, the change in systolic ambulatory blood pressure (ABP) hemodynamic response to ACE inhibitors [9], as well as
was 4.6 mm Hg (–5.7 to 14.9, P 5 0.95), and diastolic ABP
the progression of renal disease [10, 11]. Furthermore,was 1.5 mm Hg (–4.5 to 7.6, P 5 0.59). No change was seen
pathways other than the ACE may be responsible forin cardiac output. However, there was a mean 14% increase
(95% CI, 3 to 26%, P 5 0.017) in GFR attributable to losartan Ang II generation, particularly in tissues and blood ves-
therapy. A concomitant fall in plasma renin activity by 32% sels. Angiotensin receptor blockers (ARBs) could over-
was seen (95% CI, –15%, – 45%, P 5 0.002). No hyperkalemia, come these shortcomings of ACE inhibitors by directly
antagonizing the AT1 receptor. In addition, because
AT2 receptors mediate the beneficial effects of Ang II,Key words: losartan, ambulatory blood pressure, renal hemodynamics,
glomerular filtration rate, AT1 receptor. by blocking the AT1 receptors with ARBs, Ang II would
be available to stimulate the AT2 receptors.Received for publication October 18, 2000
It is not known whether the addition of ARB in pa-and in revised form January 5, 2001
Accepted for publication January 11, 2001 tients with chronic renal failure who have persistent pro-
teinuria despite ACE inhibitor therapy has beneficialÓ 2001 by the International Society of Nephrology
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Fig. 1. Trial design.
effects on the kidney. Accordingly, we tested the hypoth- was approved by the Institutional Review Board, and
all patients gave written informed consent.eses that AT1 receptor is stimulated even in patients
with a maximally recommended dose of ACE inhibitor
Measurementsand that this stimulation can be abrogated by the addi-
Ambulatory blood pressure monitoring. Ambulatorytion of ARBs. Ambulatory blood pressures, proteinuria,
blood pressures (ABPs) were recorded every 20 minutesGFR, cardiac output, renin, and aldosterone were mea-
during the day (6 a.m. to 10 p.m.) and every 30 minutessured to determine whether losartan can offer additional
during the night (10 p.m. to 6 a.m.) using a Spacelabprotection in patients treated with a maximal dose of
90207 ABP monitor (SpaceLabs Medical Inc., Redmond,ACE inhibitors.
WA, USA). The accuracy of ABP was determined by
an auscultatory method using a T piece connected to a
mercury sphygmomanometer. Data were analyzed usingMETHODS
ABP Report Management System software, versionSubjects
1.03.05 (SpaceLabs Medical Inc.). ABP and heart rates
Patients between the ages of 18 to 80 years who had were averaged over the entire course of recording.
proteinuria of $1 g/day, hypertension defined as mean Glomerular filtration rate. Glomerular filtration rates
arterial pressure $97 mm Hg, and serum potassium of were measured by iothalamate clearance. A continuous
#5.5 mEq/L and who were on lisinopril therapy of 40 subcutaneous infusion at a rate of 125 mL/hour was
mg/day for more than three months were eligible for the started after a bolus intravenous injection 24 hours prior
study. Patients who had previously received ARBs or to the actual measurements. The following day, six sam-
with estimated creatinine clearance of ,30 mL/min were ples of plasma were collected at times 0.0, 1.0, 1.5, 2.0,
2.5, and 3.0 hours while the subjects were water loaded.excluded.
Plasma iothalamate concentrations were analyzed using
Protocol a previously reported high-performance liquid chroma-
tography technique [12]. The ratio of infusion rate toThe study was a two period, cross-over, randomized
steady-state plasma concentration yielded the iothala-controlled trial (Fig. 1). Patients received either a se-
mate clearance. The average of these six collections wasquence of losartan 50 mg/day 3 weeks, a two-week wash-
expressed as the GFR.out, placebo 3 4 weeks or placebo 3 4 weeks, two-week
Plasma renin activity and plasma aldosterone. Plasmawashout, and losartan 50 mg/day 3 4 weeks. Lisinopril
renin activity was measured with a Clinical Assays Gamma-
40 mg/day along with other antihypertensive therapy was Coat radioimmunoassay kit (Baxter Healthcare, McGaw
continued throughout the trial. Before and after each Park, IL, USA). The PA concentration was measured
period GFR, plasma renin activity (PRA), plasma aldo- by radioimmunoassay with antiserum from Diagnostic
sterone (PA), 24-hour urine collection for protein, creati- Products Corp. (Los Angeles, CA, USA).
nine, Na, K, and urea, cardiac output (Qc), weight, and
Cardiac outputambulatory blood pressures were measured. One week
after starting, therapy patients were called for evaluation The cardiac output (Qc) was measured by the soluble-
gas (acetylene) rebreathing technique, in triplicate at restof blood pressure (BP) and serum chemistries. The study
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Table 1. Baseline Characteristicsin a sitting position [13]. This method for measurement of
Qc estimates pulmonary blood flow and pulmonary tis- Parameter Mean6SD or (N)
sue volume by the Fick principle. The basis for these Age years 5369
Males/females 14/16methods is that the soluble gas is taken up by lung tissue
Ethnicity 6 white, 10 blackand by blood flowing through the lungs. Because the
BMI kg/m2 3865.7
blood entering the lungs is assumed to contain no foreign Etiology of CRF Diabetes (12), glomerulo-
nephritides (4)gas and the blood leaving the lungs is assumed to contain
Antihypertensive medications Calcium channel blockers (12),the gas in direct proportion to its solubility and the mea-
all on Lisinopril 40 mg/day b blockers (6), a blockers (5),
sured partial pressure, it is possible to calculate the arte- loop diuretics (10), thiazide
diuretics (3)rial-venous difference. In combination with the measure-
Number of antihypertensives 3.1361.2ment of the rate of disappearance of the gas from the
Seated BP mm Hg 156618/88612
lung-rebreathing bag system, the blood flow can be calcu- Seated pulse rate beats/min 77611
Standing BP mm Hg 153622/90615lated. Thus, two distinct steps in analysis are required:
Standing pulse rate beats/min 83613determination of the total lung-bag system volume and
Baseline serum creatinine mg/dL 2.060.8
the calculation of the rate of uptake of acetylene. Resting cardiac output L/min 6.661.6
Resting cardiac index L/min/m2 2.960.5A known volume (1500 mL) of gas mixture containing
30% oxygen, 9% helium, 0.5% acetylene, and balance Abbreviations are: BMI, body mass index; CRF, chronic renal failure; BP,
blood pressure.nitrogen is drawn into a calibrated volume syringe, and
a bag is filled with this gas. The subjects rebreathe this
mixture for 20 to 25 seconds till helium concentration
reaches a plateau. The gas concentrations of helium and that losartan will decrease proteinuria by at least 25%
acetylene are measured in real time using a gas mass- compared with placebo treatment. Our study had 87%
spectrophotometer (Marquette Electronics, Inc., Mil- power to detect such a change with a sample size of 16
waukee, WI, USA) connected to a computer with an and a 0.050 two-sided significance level [18]. Validation
analog to digital conversion board. Data are sampled at studies have shown coefficient of variation between days
20 Hz and stored to a memory file. Using computing of iothalamate clearance by our method to be 7.7% (ab-
software (First Breath Software, version 2; First Breath stract; Agarwal et al, J Am Soc Nephrol 11:55A, 2000).
Inc.), the data are analyzed to calculate the Qc. This gave us a power of 78% to detect a 6% change in
Laboratory analysis. Serum chemistries, complete placebo-adjusted GFR using a sample size of 16 and a
blood counts, urine protein, electrolytes, urea, and creati- 0.05 two-sided significance level [18].
nine were measured by our hospital laboratory using
routine methods. Data for proteinuria and other electro-
RESULTSlyte excretions were normalized to grams of creatinine
in urine to account for the variability in urine collections. Seventeen patients were enrolled, of whom 16 com-
pleted the study (Table 1). One patient could not keep
Statistical analysis scheduled appointments after the first GFR and ABP
measurements and was dropped from the study. TheAnalysis of variance model was used to test the sig-
nificance of changes with losartan therapy. Carryover average duration of lisinopril exposure prior to enroll-
ment into the study was 18 6 6 months (range 3.5 toeffects were tested and found to be nonsignificant. The
normality and homogeneity of variance assumptions of 26.6 months).
the analysis of variance models were tested by the Sha-
Effects on laboratory and 24-hour urine parameterspiro-Wilk statistic and the Levene test, respectively. All
tests were two sided at an a level of 0.05. Data on protein- Body weight, hemoglobin, or serum chemistries did
not change with add-on losartan therapy (Table 2). Ofuria, GFR, PRA, and PA were log transformed prior
to analysis to satisfy the assumption of normality. All note, potassium levels did not increase with losartan.
Baseline Na excretion was high, reflecting the usual dietanalyses were adjusted for the placebo control, and 95%
confidence intervals were constructed [14]. All statistical of these patients. Urine urea nitrogen excretion rates
also reflected the high protein intake in these patients.analysis were carried out using standard procedures on
Statistica for Windows, release 4.5 (StatSoft, Inc., Tulsa, Urine protein excretion rate did not change over one
month of losartan therapy (Fig. 2).OK, USA) [15].
A paradigm of titration of ACE inhibitors to antipro-
Effects on systemic and renal hemodynamicsteinuric rather than antihypertensive effect is emerging
[16], and studies in patients with proteinuria show a 54% There was no overall improvement in systolic or dia-
stolic ABP compared with placebo. Resting seated car-fall in proteinuria within one month of starting enalapril
[17]. Therefore, the primary hypothesis of this study was diac output remained unchanged (Table 3). Average
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Table 2. Changes in laboratory parameters and weight
Placebo Losartan
Placebo
Post- Post- corrected
Baseline placebo Baseline losartan change 95% CI P
Body weight kg 11966.1 11966.2 11866.1 11866.2 10.1 22.4, 2.6 0.92
Blood parameters
Na mEq/L 14160.6 14160.6 14060.7 14160.7 10.29 21.6, 2.2 0.76
K mEq/L 4.160.13 4.160.10 4.360.10 4.360.15 1.06 20.34, 0.46 0.75
HCO3 mEq/L 24.360.72 25.460.94 25.161 24.660.87 21.6 23.8, 0.72 0.18
Creatinine mg/dL 2.060.2 2.160.21 2.160.22 2.160.23 20.11 2.31, 10.10 0.30
Glucose mg/dL 173621 132615 159617 161626 142 226, 1109 0.22
Uric acid mg/dL 7.760.48 7.860.57 8.160.46 8.760.99 10.37 21.05, 11.80 0.59
Hb g/dL 12.660.49 12.660.54 12.960.52 12.660.53 20.36 21.15, 10.43 0.36
Urinary parameters (expressed as /g creatinine)
Na mEq/24 h 224629 201624 187617 213622 110 220, 140 0.485
K mEq/24 h 6668 63 66 55 67 61 66 0.74 25.5, 7.0 0.803
Urea g/24 h 11.261.7 10.461.2 9.461.0 12.061.3 10.74 20.91, 2.4 0.353
Protein g/24 h 3.660.71 3.0860.55 3.5660.75 3.4260.87 11% 220%, 128% 0.89
Data are mean 6 SEM.
Fig. 2. Twenty-four-hour urine protein excre-
tion rate normalized before and after placebo,
and before and after losartan administration.
No overall drug effect was seen (P 5 0.89).
Table 3. Systemic and renal hemodynamic parameters
Placebo Losartan
Placebo
Post- Post- corrected
Baseline placebo Baseline losartan change 95% CI P
Systolic ABP mm Hg 15165 14963 14864.25 15166 14.6 25.7, 14.9 0.95
Diastolic ABP mm Hg 8362 8262 8263 8363 11.5 24.5, 7.6 0.59
GFR lothalamate clearance mL/min 69610 6469 6369 68611 114% 3%, 26% 0.017
Resting seated cardiac output L/min 6.960.39 6.760.29 6.860.42 6.660.38 10 20.9, 10.9 0.99
Data are mean 6 SEM.
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Fig. 4. Diastolic 24-hour ambulatory blood pressures before (d) orFig. 3. Systolic 24-hour ambulatory blood pressures before (d) or after
after the one month (s) placebo (A) or losartan therapy (B) period.the one month (s) placebo (A) or losartan therapy (B) period. No
No change can be seen.change can be seen.
Table 4. Supine plasma renin activity and plasma aldosterone
Placebo Losartan
Placebo
Post- Post- corrected
Baseline placebo Baseline losartan change 95% CI P
Plasma renin activity ng/mL/h 0.7561.51 1.1461.63 1.5361.61 0.9461.79 258.8% 231.5%, 275.3% 0.003
Plasma aldosterone ng/mL 5.7061.22 6.1561.22 5.0261.30 5.6561.22 17.6% 210.5%, 29.2% 0.423
PA/PRA ratio 7.8261.64 5.4261.68 3.2961.69 5.9861.92 1175% 156%, 1386% 0.003
Data are geometric mean 6 SEM. PRA denotes plasma renin activity and PA denotes plasma aldosterone.
ABPs for the 16 patients are shown in Figures 3 and 4, change in aldosterone. However, because of a fall in
demonstrating little change in blood pressure trends. In renin, the PA/PRA ratio increased by 175%.
contrast, the placebo-corrected GFR improved by 14%.
GFR tended to fall during placebo and rise with add-on
DISCUSSIONlosartan therapy.
There is uncertainty regarding the usefulness of com-
Effects on the renin-aldosterone system bination ACE inhibition and ARB therapy in patients
with chronic renal failure [19]. Therefore, we designedThe renin-aldosterone system had remarkable effects
(Table 4). Renin fell by 32%, despite that there was no the study to examine the benefit of add-on therapy in
Agarwal: Add-on Ang I receptor blockade with maximized ACE inhibition 2287
those patients who had persistent proteinuria despite patients who were followed in the clinic for a longer
duration. Data were obtained on 13 patients who had amaximal ACE inhibition. Because proteinuria by itself
is damaging to the kidney [20] and is also a marker of follow-up from 4 to 12 months. Of the eight patients
who continued on losartan, proteinuria declined to lessprogressive renal disease [2], it was reasonable to assume
that add-on losartan therapy is likely to benefit this sub- than 50% of baseline in four patients, declined ,50%
in two, and increased in the other two. None of thesegroup of patients particularly. Because this was an exper-
imental study and not an outcomes study, these patients patients progressed to end-stage renal disease or doubled
their creatinine. Of the five patients who discontinuedwere studied intensively with measurements of GFR and
the renin-angiotensin-aldosterone system (RAAS) and losartan, one reached end-stage renal disease, one dou-
bled his creatinine, one had an increase in proteinuria,systemic hemodynamic monitoring. We reasoned that if
losartan would have an effect, it would perturb the and two had ,50% reduction in proteinuria. Obviously,
these observational data need to be interpreted withRAAS first and then the renal circulation; systemic he-
modynamics and proteinuria would be less sensitive mea- caution; nevertheless, there appears to be a trend to-
wards improvement in proteinuria over the longer term.sures of RAAS perturbations because of the relatively
low dose of losartan used. However, the primary objec- Blood pressure was poorly controlled at baseline de-
spite an average of 3.1 medications and did not improvetive of the study was to detect a change in proteinuria
with add-on losartan therapy. with the addition of losartan. This is not surprising given
that these patients had severe hypertension and wereThe most important finding of our study was a lack
of response to the add-on losartan therapy on 24-hour administered a relatively low dose of ARB. Our study
was not designed to address the question of loweringprotein excretion over the short term. Unlike several
other studies reported in the literature, only those pa- blood pressure to improve proteinuria, rather than to
assess the effect of additional Ang II antagonism in pa-tients who were taking the maximal dose of the ACE
inhibitor lisinopril were studied. For example, combina- tients with persistent proteinuria despite a maximum
dose ACE inhibition.tion therapy in normotensive volunteers demonstrates
an additional increase in PRA when losartan was added Most important, our patients had substantially more
severe disease, worse hypertension, and lower GFRsto submaximal captopril therapy [21]. Also, normoten-
sive volunteers do not have sympathetic activation, in- than the previously mentioned studies and that likely
accounts for the different response to proteinuria. Fur-flamed kidneys, or endothelial dysfunction, unlike what
may be present in hypertensive, obese, chronic renal thermore, our study included only those patients in
whom the dose of lisinopril was maximized for at leastfailure patients, which likely accounts for the differences.
This current study is also at variance with what is seen three months.
An interesting finding of the study was a fall in PRAin patients with IgA nephropathy with proteinuria [22].
In the latter study, eight patients were treated with small and a concomitant rise in GFR, although this was not
the prime target question. These results were unexpecteddoses of four different ACE inhibitors and had an addi-
tional antiproteinuric effect when losartan was added. but may be explained by at least three factors. First, this
combination of a fall in PRA and improvement in GFRIn both of these studies, a combination therapy of ACE
inhibitor and ARB was more effective that either alone may occur due to reduction in the renal sympathetic
nerve activity in these patients [5], that is, elevated inin reducing proteinuria. However, neither study max-
imized the dose of ACE inhibitor prior to adding losar- patients with chronic renal failure [24] and reduced by
the use of ACE inhibitors [5]. Furthermore, obesity itselftan. Thus, two drugs working on the same (RAAS) hor-
monal system can only be called additive when one of can increase sympathetic nerve activity in the human
kidneys [25]. Mechanisms of improvement in sympa-them is at the top of the dose response. On the other
hand, other studies that have compared ACE inhibitors thetic activation may be due to either improved renal
perfusion, reduced ischemia, and reduced adenosinewith losartan in patients with type II diabetes mellitus,
hypertension, and early nephropathy have shown similar generation [26] that may be mediated by stimulation of
the AT2 receptors [27]. Alternatively, this reduction maymagnitude of blood pressure reduction and urine albu-
min excretion, but less cough and hyperuricemia in pa- be due to reduced AT1 receptor activation in the brain
directly either by Ang II or through Ang III [28]. Becausetients randomized to losartan [23].
The current study had adequate power to detect a amlodipine, which also improves renal perfusion, does
not reduce sympathetic nerve activity, it is thought that25% fall in proteinuria, and it is unlikely that this effect
was missed. Nevertheless, in these patients with severe the central effects of ARBs are more important [26].
Furthermore, losartan can block peripheral neuroadren-proteinuria, it is possible that the duration of exposure
to losartan over the course of the study was too short ergic transmission [29]. Lisinopril, which is water soluble
and predominantly renally excreted [30], may not crossto show substantial changes in proteinuria. Indeed, over
the longer term, proteinuria appeared to fall in those the blood–brain barrier, unlike losartan, which is more
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